HIV Prevention Drug Lenacapavir Faces USAID Funding Crisis 2026

HIV prevention drug lenacapavir, a twice-yearly injectable PrEP, could reduce new HIV cases dramatically, but USAID funding cuts are preventing access for those most in need, according to experts at the Aids 2026 Conference in Rio de Janeiro. This breakthrough medication offers hope for millions, yet global health funding shortages threaten its rollout.

Why Lenacapavir Is a Game-Changer in HIV Prevention

Lenacapavir, an injectable form of PrEP, requires only two injections per year, making it far more accessible than daily pills or bimonthly shots. The World Health Organization (WHO) recommended in 2025 that governments prioritize expanding access to this drug, citing its potential to overcome barriers like poverty, stigma, and geographic isolation.

For populations in rural areas or marginalized communities, adhering to a daily oral PrEP regimen is often impossible. Lenacapavir eliminates this burden, offering near-universal protection with minimal healthcare visits.

Clinical Efficacy and WHO Endorsement

PrEP, including lenacapavir, is 99% effective in preventing sexually transmitted HIV when taken consistently. The WHO’s mathematical modeling study, conducted with the United Nations, estimated that widespread lenacapavir availability could prevent 41% of new HIV infections in South Africa, Zimbabwe, and western Kenya.

Despite this promise, the drug remains largely unavailable outside clinical trials, and the recent dissolution of USAID has crippled global HIV prevention funding.

Impact of USAID Cuts on HIV Prevention Access

USAID provided 73% of donor-funded resources for HIV prevention globally, according to a study in the Lancet Global Health. The Trump administration’s decision to dissolve USAID has led to a dramatic decline in investment, leaving millions without access to lenacapavir and other essential PrEP options.

Experts at the conference emphasized that without sustained funding, the 41% infection reduction potential will remain unrealized, exacerbating the global HIV epidemic.

Funding Shortfall: A Comparative Look

Key Takeaways for Global Health Policy

• Lenacapavir could prevent 41% of new HIV infections in high-burden regions.
• USAID cuts have reduced donor funding by nearly three-quarters, halting scale-up efforts.
• Alternative funding sources and public-private partnerships are urgently needed.
• Community-based delivery models can help reach marginalized populations.
• Advocacy for policy change is critical to restore HIV prevention budgets.

FAQ